INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236601, 'Ezetimibe', 'Loteprednol etabonate', 'Unknown', 'None', 'DDInter', '-', '', '', 'Unknown', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236831/', '', 'Amlodipine, Ramipril, Atorvastatin, Lovastatin, Perindopril, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Cholestyramine, Fenofibrate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236602, 'Rosuvastatin', 'Loteprednol etabonate', 'Unknown', 'None', 'DDInter', '-', '', '', 'Unknown', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236832/', '', 'Amlodipine, Ramipril, Atorvastatin, Lovastatin, Perindopril, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Cholestyramine, Fenofibrate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236603, 'Tiotropium', 'Loteprednol etabonate', 'Unknown', 'None', 'DDInter', '-', '', '', 'Unknown', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236833/', '', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Beclomethasone dipropionate, Terbutaline, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Orciprenaline, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236604, 'Fluticasone', 'Loteprednol etabonate', 'Unknown', 'None', 'DDInter', '-', '', '', 'Unknown', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236834/', '', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236605, 'Abciximab', 'Alemtuzumab', 'Moderate', 'Coadministration of alemtuzumab with antiplatelet or anticoagulant drugs may increase the risk of bleeding.  Use of alemtuzumab alone has been associated with autoimmune and hemolytic anemia, thrombocytopenia, prolonged myelosuppression, bone marrow aplasia, hemophilia, and pancytopenia.  The mechanism for this interaction has not been clearly delineated, but is presumably due to additive antiplatelet/anticoagulant effects.', 'DDInter', 'Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs.  Patients should be monitored for increased anticoagulant effects and bleeding complications.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236841/', '', 'Iloprost, Treprostinil, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236606, 'Heparin (flush)', 'Abciximab', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', 'DDInter', 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Caution and monitoring (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236848/', '', 'Acenocoumarol, Selexipag', 'Abciximab, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236607, 'Amphotericin B (lipid complex)', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', 'DDInter', 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237031/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236608, 'Amphotericin B (lipid complex)', 'Bacitracin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237032/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236609, 'Amphotericin B (lipid complex)', 'Budesonide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia.', 'DDInter', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.  Potassium supplementation may be necessary.  Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237034/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, Salbutamol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236610, 'Amphotericin B (lipid complex)', 'Chlorothiazide', 'Moderate', 'The concomitant use of amphotericin and potassium-wasting diuretics may result in increased risk of hypokalemia due to additive effects.', 'DDInter', 'Patients receiving diuretics with amphotericin should be monitored closely for development of hypokalemia.  Potassium supplementation may be necessary.  Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Patients receiving diuretics with amphotericin should be monitored closely for development of hypokalemia.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237035/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236611, 'Amphotericin B (lipid complex)', 'Colistimethate', 'Moderate', 'Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.', 'DDInter', 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237036/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236612, 'Iloperidone', 'Amphotericin B (lipid complex)', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237039/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Probenecid, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236613, 'Isavuconazonium', 'Amphotericin B (lipid complex)', 'Minor', 'Imidazole and triazole antifungal agents may antagonize the effects of amphotericin.', 'DDInter', 'Caution is urged if combination therapy is necessary.', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237043/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, Trichlormethiazide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236614, 'Amphotericin B (lipid complex)', 'Mesoridazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237045/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236615, 'Amphotericin B (lipid complex)', 'Micafungin', 'Moderate', 'The concomitant use of micafungin and amphotericin B may increase systemic exposure to amphotericin.  The mechanism is unknown.  Coadministration resulted in a 30% increase in amphotericin exposure.  Micafungin pharmacokinetics were not affected.', 'DDInter', 'The European manufacturers recommend that these drugs should only be coadministered if the potential benefits outweigh the risks.  Patients should be monitored for amphotericin toxicity.  The same precaution may be applicable during therapy with other forms of amphotericin B such as liposomal or lipid complex, although clinical data are lacking.', 'Others', 'The European manufacturers recommend that these drugs should only be coadministered if the potential benefits outweigh the risks.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237048/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236616, 'Amphotericin B (lipid complex)', 'Perphenazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237049/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, Probenecid, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236617, 'Amphotericin B (lipid complex)', 'Polymyxin B', 'Moderate', 'Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.', 'DDInter', 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237050/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Tetracycline, Rifamycin, Ciprofloxacin, Chloramphenicol, Chlorhexidine, Ofloxacin, Tetracycline, Ciprofloxacin, Chlorhexidine, Chloramphenicol, Tinidazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236618, 'Amphotericin B (lipid complex)', 'Posaconazole', 'Minor', 'Imidazole and triazole antifungal agents may antagonize the effects of amphotericin.', 'DDInter', 'Caution is urged if combination therapy is necessary.', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237051/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Darunavir, More', 'Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236619, 'Amphotericin B (lipid complex)', 'Prochlorperazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237052/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236620, 'Amphotericin B (lipid complex)', 'Telavancin', 'Moderate', 'Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.', 'DDInter', 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237054/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236621, 'Amphotericin B (lipid complex)', 'Triflupromazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237057/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, Ciclopirox, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236622, 'Abemaciclib', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237061/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236623, 'Abemaciclib', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237129/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236624, 'Abemaciclib', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237130/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236625, 'Pralsetinib', 'Acetaminophen', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237143/', '', 'Salicylic acid, Choline salicylate, Ziconotide, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid, Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, More', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236626, 'Berotralstat', 'Aripiprazole', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', 'DDInter', 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.  Clinical and laboratory monitoring are recommended following the initiation of berotralstat, and the individual dosage of the concomitant agents adjusted as needed.', 'Metabolism', 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237152/', '', 'Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, Molindone, Paliperidone', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236627, 'Brigatinib', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', 'DDInter', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237155/', '', 'Fluphenazine, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Lurasidone, More', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236628, 'Aripiprazole', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237173/', '', 'Amisulpride, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236629, 'Aripiprazole', 'Methohexital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237174/', '', 'Amisulpride, Pimavanserin', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236630, 'Metreleptin', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', 'DDInter', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237176/', '', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Pimozide, Trifluoperazine, Paliperidone, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236631, 'Oritavancin', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', 'DDInter', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237182/', '', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Pimozide, Trifluoperazine, More', 'Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236632, 'Palbociclib', 'Aripiprazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these isoenzymes.', 'DDInter', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The manufacturer recommends that aripiprazole dosage be reduced to one-half the normal dosage during concomitant administration with ketoconazole or quinidine, and additional dosage adjustments be made based on clinical evaluation.  No dosage recommendations are available for concomitant administration with less potent CYP450 2D6 or 3A4 inhibitors.', 'Metabolism', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237184/', '', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236633, 'Pralsetinib', 'Aripiprazole', 'Moderate', 'It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.', 'DDInter', 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.  ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Others', 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237187/', '', 'Amisulpride, Loxapine, Molindone, Thiothixene', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236634, 'Relugolix', 'Aripiprazole', 'Moderate', 'It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.', 'DDInter', 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.  ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Others', 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237189/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Norethisterone, Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, Exemestane, Fulvestrant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236635, 'Safinamide', 'Aripiprazole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237190/', '', 'Amisulpride, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236636, 'Zanubrutinib', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', 'DDInter', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237198/', '', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, More', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236637, 'Abiraterone', 'Berotralstat', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat.  Berotralstat is a substrate of both P-gp and BCRP.', 'DDInter', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.  Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237204/', '', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Exemestane', 'Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236638, 'Abiraterone', 'Celecoxib', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of celecoxib, which is primarily metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of celecoxib should be considered.', 'DDInter', 'Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor.  Dosage adjustments may be required if an interaction is suspected.  Patients should be advised to notify their physician if they experience potential signs and symptoms of celecoxib toxicity such as abdominal pain, black or tarry stools, nausea, vomiting, lethargy, fluid retention, swelling of legs, and worsening heart failure.', 'Metabolism', 'Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237208/', '', 'Darolutamide, Abarelix, Relugolix, Degarelix, Nilutamide, Aminoglutethimide', 'Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Opium, Ibuprofen, Pentazocine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236639, 'Abiraterone', 'Morphine', 'Major', 'Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including hypotension, respiratory and CNS depression, profound sedation, coma, and death.  The proposed mechanism may involve inhibition of the intestinal P-gp efflux transporter, resulting in enhanced oral bioavailability of morphine, a P-gp substrate.  The interaction may be more significant for orally administered morphine.  According to some authorities, the concomitant use of a P-gp inhibitor with oral morphine may increase the systemic exposure of morphine by approximately 2-fold.', 'DDInter', 'Caution is recommended whenever morphine, particularly orally administered morphine, is used concomitantly with a P-gp inhibitor.  Close clinical and laboratory monitoring should be considered whenever a P-gp inhibitor is added to or withdrawn from therapy, and the morphine dosage adjusted as necessary.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation that may be greater than otherwise expected.  In addition, patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them.', 'Absorption', 'Caution is recommended whenever morphine, particularly orally administered morphine, is used concomitantly with a P-gp inhibitor.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237220/', '', 'Darolutamide, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Degarelix, Nilutamide, Aminoglutethimide', 'Opium, Diphenoxylate, Difenoxin, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236640, 'Ethanol', 'Posaconazole', 'Moderate', 'Concomitant use of alcohol and posaconazole administered in the form of delayed-release oral suspension may lead to a faster release of posaconazole.', 'DDInter', 'MANAGEMENT Administration of posaconazole as delayed-release oral suspension with alcohol is not recommended.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237248/', '', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More', 'Fluconazole, Caspofungin, Amphotericin B, Itraconazole, Miconazole, Micafungin, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236641, 'Ethanol', 'Sulfamethoxazole', 'Moderate', 'First-generation sulfonylureas have been reported to cause facial flushing when administered with alcohol by inhibiting acetaldehyde dehydrogenase and subsequently causing acetaldehyde accumulation.  Since sulfamethoxazole is chemically related to first-generation sulfonylureas, a disulfiram-like reaction with products containing sulfamethoxazole is theoretically possible.', 'DDInter', 'Patients should be alerted to the potential for this interaction and although the risk for this interaction is minimal, caution is recommended while taking sulfamethoxazole-trimethoprim concomitantly with alcohol.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237252/', '', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Rifampicin, Rifabutin, Ethambutol, Pyridoxine, Pretomanid, Aminosalicylic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236642, 'Haloperidol', 'Botulinum toxin type A', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', 'DDInter', 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237255/', '', 'Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium', 'Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236643, 'Botulinum toxin type A', 'Botulinum toxin type A', 'Moderate', 'The effect of administering different botulinum neurotoxin serotypes concurrently or within several months of one another is unknown.  Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.', 'DDInter', 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237256/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236644, 'Botulinum toxin type B', 'Botulinum toxin type A', 'Moderate', 'The effect of administering different botulinum neurotoxin serotypes concurrently or within several months of one another is unknown.  Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.', 'DDInter', 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237257/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236645, 'Bacillus calmette-guerin substrain tice live antigen', 'Paclitaxel (protein-bound)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237262/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236646, 'Entrectinib', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', 'DDInter', 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237267/', '', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236647, 'Paclitaxel (protein-bound)', 'Osilodrostat', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', 'DDInter', 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237294/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236648, 'Paclitaxel', 'Paclitaxel (protein-bound)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.', 'DDInter', 'Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.', 'Synergism', 'Caution is advised during concomitant use of agents with neurotoxic effects.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237295/', '', 'Irinotecan', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236649, 'Paclitaxel (protein-bound)', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', 'DDInter', 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237297/', '', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236650, 'Pazopanib', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration of substrates of CYP450 3A4, 2D6, or 2C8 with pazopanib may increase their plasma concentrations.  The mechanism is inhibition of CYP450-mediated metabolism by pazopanib.', 'DDInter', 'Due to the potential for adverse effects, the concomitant use of pazopanib with drugs that have narrow therapeutic ranges and that are substrates of CYP450 3A4, 2D6, or 2C8 is not recommended.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237298/', '', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236651, 'Pralsetinib', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237308/', '', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236652, 'Selinexor', 'Paclitaxel (protein-bound)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.', 'DDInter', 'Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.', 'Synergism', 'Caution is advised during concomitant use of agents with neurotoxic effects.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237330/', '', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Aflibercept, Anagrelide, Panobinostat, Venetoclax, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236653, 'Troglitazone', 'Paclitaxel (protein-bound)', 'Moderate', 'Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is metabolized by these isoenzymes.', 'DDInter', 'Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237342/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236654, 'Yellow Fever Vaccine', 'Paclitaxel (protein-bound)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237349/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236655, 'Varicella Zoster Vaccine (Recombinant)', 'Paclitaxel (protein-bound)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237350/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236656, 'Adalimumab', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237356/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236657, 'Adalimumab', 'Lisocabtagene maraleucel', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237378/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236658, 'Adalimumab', 'Melphalan flufenamide', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237381/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236659, 'Adalimumab', 'Promazine', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237398/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236660, 'Adalimumab', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237438/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236661, 'Adalimumab', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237439/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236662, 'Isotretinoin', 'Drospirenone', 'Moderate', 'Isotretinoin may decrease the plasma concentrations of contraceptive progestins.  The potential mechanism of interaction has not been established.', 'DDInter', 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.  Combination oral contraceptive pills are considered an acceptable primary form of contraception and may be used (please refer to the product labeling for list of acceptable primary and secondary forms of contraception).  Due to the teratogenic risk of isotretinoin, females of reproductive potential must use two methods of effective contraception, at least one of which must be a primary form, for at least 1 month prior to initiation of isotretinoin therapy, during therapy, and for 1 month after discontinuing therapy.', 'Others', 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237845/', '', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, Etonogestrel, More', 'Minocycline, Clindamycin, Vitamin A, Dexamethasone, Fluorometholone, Tretinoin, Dapsone, Methylprednisolone, Azelaic acid, Adapalene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236663, 'Isotretinoin', 'Levonorgestrel', 'Moderate', 'Isotretinoin may decrease the plasma concentrations of contraceptive progestins.  The potential mechanism of interaction has not been established.', 'DDInter', 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.  Combination oral contraceptive pills are considered an acceptable primary form of contraception and may be used (please refer to the product labeling for list of acceptable primary and secondary forms of contraception).  Due to the teratogenic risk of isotretinoin, females of reproductive potential must use two methods of effective contraception, at least one of which must be a primary form, for at least 1 month prior to initiation of isotretinoin therapy, during therapy, and for 1 month after discontinuing therapy.', 'Others', 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237850/', '', 'Minocycline, Clindamycin, Vitamin A, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Methylprednisolone, Azelaic acid, Adapalene', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, Etonogestrel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236664, 'Isotretinoin', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237856/', '', 'Minocycline, Clindamycin, Vitamin A, Fluorometholone, Azelaic acid, Adapalene', 'Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236665, 'Fentanyl', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237860/', '', 'Azelastine, Ketotifen, Terfenadine, Astemizole', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine, Naltrexone, Acetaminophen, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236666, 'Fentanyl', 'Berotralstat', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme.  Increased fentanyl concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Conversely, discontinuation of a CYP450 3A4 inhibitor could decrease fentanyl plasma concentrations, decrease opioid efficacy, and possibly even lead to a withdrawal syndrome in patients who had developed physical dependence to fentanyl.', 'DDInter', 'Patients receiving fentanyl with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed.  This is particularly important when an inhibitor is added after a stable dose of fentanyl has been achieved.  Some authorities recommend avoiding concomitant use of fentanyl during and for 2 weeks after treatment with itraconazole.  Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur, such as dizziness, confusion, fainting, extreme sedation, unresponsiveness, bradycardia, slow or difficult breathing, and shortness of breath.  When discontinuing CYP450 3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.  Patients treated with transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', 'Metabolism', 'Patients receiving fentanyl with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237866/', '', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236667, 'Fentanyl', 'Dextromethorphan', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237871/', '', 'Benzonatate, Dalfampridine, Inotersen, Tafamidis', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Acetylsalicylic acid, Acetaminophen, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236668, 'Fentanyl', 'Ergotamine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237874/', '', 'Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236669, 'Fentanyl', 'Levodopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237883/', '', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Naltrexone, Acetaminophen, Ibuprofen, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236670, 'Fentanyl', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237887/', '', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236671, 'Fentanyl', 'Pitolisant', 'Moderate', 'Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Pitolisant is a borderline/weak inducer of CYP450 3A4.', 'DDInter', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.  Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.  It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.', 'Metabolism', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237896/', '', 'Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, More', 'Dalfampridine, Inotersen, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236672, 'Fentanyl', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237897/', '', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Oxymorphone, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236673, 'Fentanyl', 'Tolevamer', 'Moderate', 'Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.', 'DDInter', 'Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.', 'Synergism', 'Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237899/', '', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236674, 'Acalabrutinib', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237913/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236675, 'Acalabrutinib', 'Berotralstat', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The dosage of acalabrutinib should be reduced to 100 mg once daily when coadministered with moderate CYP450 3A4 inhibitors.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237915/', '', 'Copanlisib, Lenvatinib, Erdafitinib, Dabrafenib, Abemaciclib, Vandetanib, Trametinib, Dacomitinib, Alectinib, Binimetinib', 'Betibeglogene autotemcel, Hyaluronidase, Lanadelumab, Human C1-esterase inhibitor, Crizanlizumab, Conestat alfa, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236676, 'Acalabrutinib', 'Heparin (flush)', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', 'DDInter', 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Caution and monitoring (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237926/', '', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More', 'Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236677, 'Acalabrutinib', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237958/', '', 'Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib', 'Acalabrutinib, Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236678, 'Acalabrutinib', 'Sunitinib', 'Major', 'Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 'Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution.  Close clinical and laboratory monitoring for bleeding complications is recommended during therapy.  Patients should be advised to promptly report any signs and symptoms of bleeding to their physician.', 'Synergism', 'Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237983/', '', 'Imatinib, Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, Sunitinib, Ripretinib, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236679, 'Acalabrutinib', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237993/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236680, 'Acalabrutinib', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237994/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236681, 'Daclatasvir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238054/', '', 'Guar gum', 'Lamivudine, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236682, 'Fluocinolone acetonide', 'Acarbose', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use.  Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.', 'DDInter', 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'Antagonism', 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238056/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Fluorometholone, Hydrocortisone butyrate, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236683, 'Simeprevir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238065/', '', 'Guar gum', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236684, 'Sofosbuvir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238067/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236685, 'Clonazepam', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238070/', '', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236686, 'Clonazepam', 'Chlorcyclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238079/', '', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 'Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236687, 'Clonazepam', 'Chlormezanone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238080/', '', 'Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236688, 'Cyclizine', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238081/', '', 'Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236689, 'Dimenhydrinate', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238085/', '', 'Lacosamide', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236690, 'Felbamate', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238088/', '', 'Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236691, 'Fenfluramine', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238089/', '', 'Lacosamide, Fenfluramine', 'Dexfenfluramine, Ephedrine, Lorcaserin, Diethylpropion, Mazindol, Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236692, 'Clonazepam', 'Methyldopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238098/', '', 'Topiramate, Ezogabine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Paramethadione, Carbamazepine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236693, 'Clonazepam', 'Osilodrostat', 'Moderate', 'Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.', 'DDInter', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238103/', '', 'Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Methsuximide, Perampanel, Phensuximide, Lamotrigine, Phenacemide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236694, 'Clonazepam', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238106/', '', 'Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236695, 'Clonazepam', 'Remimazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238108/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236696, 'Bromocriptine', 'Zafirlukast', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of bromocriptine.  Orally administered bromocriptine is extensively metabolized in the gastrointestinal tract and liver by CYP450 3A4, with approximately 93% of the absorbed dose undergoing first-pass metabolism and only the remaining 7% reaching systemic circulation.  As such, inhibitors of CYP450 3A4 may markedly reduce the metabolic clearance of bromocriptine.', 'DDInter', 'Caution and close monitoring for development of adverse effects are advisable during coadministration of bromocriptine with CYP450 3A4 inhibitors, and the bromocriptine dosage adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238118/', '', 'Apomorphine, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Pergolide, Safinamide, More', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236697, 'Drospirenone', 'Zafirlukast', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.', 'DDInter', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238121/', '', 'Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, More', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236698, 'Fedratinib', 'Zafirlukast', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fedratinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19 and flavin-containing monooxygenase 3 (FMO3).', 'DDInter', 'Caution is advised when fedratinib is used with CYP450 3A4 inhibitors, particularly those that may also inhibit CYP450 2C19 (e.g., amiodarone, cimetidine, fexinidazole, isoniazid, osilodrostat, rucaparib) or if combined with other drugs that can inhibit CYP450 2C19 (e.g., esomeprazole, fenofibrate, fluoxetine, lansoprazole, letrozole, moclobemide, omeprazole, parecoxib, ticlopidine).  Patients should be monitored for adverse reactions such as nausea, vomiting, diarrhea, anemia, thrombocytopenia, neutropenia, encephalopathy (including Wernicke''s), liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations, increased blood creatinine, and secondary malignancies.  Dosage adjustment or treatment interruption may be required based on patient tolerance and response in accordance with the prescribing information.', 'Metabolism', 'Caution is advised when fedratinib is used with CYP450 3A4 inhibitors, particularly those that may also inhibit CYP450 2C19 (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238122/', '', 'Dacomitinib, Pacritinib, Vemurafenib, Vandetanib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Regorafenib, More', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236699, 'Zafirlukast', 'Selinexor', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.', 'DDInter', 'Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.', 'Synergism', 'Caution is advised during concomitant use of agents with neurotoxic effects.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238133/', '', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Niraparib, More', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (236700, 'Somatotropin', 'Astemizole', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238140/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
